Skip NavigationSkip to Content
Return Return to Search Results

Utility of F-18-fluoroestradiol (F-18-FES) PET/CT imaging as a pharmacodynamic marker in patients with refractory estrogen receptor-positive solid tumors receiving Z-endoxifen therapy

  1. Author:
    Lin, F. I.
    Gonzalez, E. M.
    Kummar, S.
    Do, K.
    Shih, J.
    Adler, Stephen
    Kurdziel, K. A.
    Ton, A.
    Turkbey, B.
    Jacobs, P. M.
    Bhattacharyya, S.
    Chen, A. P.
    Collins, J. M.
    Doroshow, J. H.
    Choyke, P. L.
    Lindenberg, M. L.

  2. Author Address

    Cancer Imaging Program, National Cancer Institute, NIH, Bethesda, MD, USA. frank.lin2@nih.gov.;Molecular Imaging Program, National Cancer Institute, Bethesda, MD, USA. frank.lin2@nih.gov.;Molecular Imaging Program, National Cancer Institute, Bethesda, MD, USA.;Division of Cancer Treatment and Diagnosis and Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.;Biometric Research Program, National Cancer Institute, NIH, Bethesda, MD, USA.;Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc., NCI Campus at Frederick, Frederick, MD, 21702, USA.;Cancer Imaging Program, National Cancer Institute, NIH, Bethesda, MD, USA.;Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Frederick, MD, USA.;Development Program, DCTD, National Cancer Institute, Bethesda, MD, USA.
    1. Year: 2017
    2. Date: Mar
    3. Epub Date: 11/23/2016
  2. Journal: European Journal of Nuclear Medicine and Molecular Imaging
    1. 44
    2. 3
    3. Pages: 500-508
  4. Type of Article: Article
  5. ISSN: 1619-7070
  1. Abstract:

    BACKGROUND: Z-endoxifen is the most potent of the metabolites of tamoxifen, and has the potential to be more effective than tamoxifen because it bypasses potential drug resistance mechanisms attributable to patient variability in the expression of the hepatic microsomal enzyme CYP2D6. 18F-FES is a positron emission tomography (PET) imaging agent which selectively binds to estrogen receptor alpha (ER-alpha) and has been used for non-invasive in vivo assessment of ER activity in tumors. This study utilizes 18F-FES PET imaging as a pharmacodynamic biomarker in patients with ER+ tumors treated with Z-endoxifen. METHODS: Fifteen patients were recruited from a parent therapeutic trial of Z-endoxifen and underwent imaging with 18F-FES PET at baseline. Eight had positive lesions on the baseline scan and underwent follow-up imaging with 18F-FES 1-5 days post administration of Z-endoxifen. RESULTS: Statistically significant changes (p = 0.0078) in standard uptake value (SUV)-Max were observed between the baseline and follow-up scans as early as 1 day post drug administration. CONCLUSION: F-FES PET imaging could serve as a pharmacodynamic biomarker for patients treated with ER-directed therapy.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1007/s00259-016-3561-8
  3. PMID: 27872957
  4. View record in Web of Science®
  5. WOS: 000394985100019

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel